Kane Biotech presents revyve wound care data

Dr. Robert Huizinga reports KANE BIOTECH SHOWCASES REVYVE™ PRECLINICAL AND CLINICAL CASE STUDY FINDINGS AT NORTH AMERICAN WOUND CARE CONFERENCES Kane Biotech Inc. recently presented novel preclinical data and clinical case observations at two major North American wound care conferences: Nurses Specialized in Wound, Ostomy and Continence Canada (NSWOCC) 44th National Conference (May 21 to May 25, 2025), and the Symposium on Advanced Wound Care (SAWC) Spring Conference (April 30 to May 4, 2025). Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve over six to 12 weeks Preclinical in vitro studies demonstrated greater than 80-per-cent reduction in protease activity, including complete inhibition of TACE and collagenase -- key factors in non-healing chronic wounds. revyve data featured in presentations and posters at NSWOCC and SAWC -- two of the leading North American conferences on wound care. Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve, including inhibition of key proteases such as matrix metalloproteinases (MMPs), elastase, collagenase and TNF-Alpha Converting Enzyme (TACE). In vitro models demonstrated: 80-per-cent reduction in MMP activity; 82-per-cent reduction in elastase activity; 100-per-cent reduction in collagenase and TACE enzyme activity. These data support continuing scientific exploration into chronic wound mechanisms, including elevated levels of tumour necrosis factor-alpha (TNF-alpha), which in chronic wounds may exceed those in acute wounds by up to 100-fold. At the NSWOCC conference, Kane showcased four case study posters, delivered an oral presentation, and hosted a booth featuring revyve antimicrobial wound gel and the XSONX wound hygiene system. The presentation, titled "Changing the Paradigm of Wound Care Through the Use of Novel Modalities," included speakers from clinical and industry backgrounds: Rosemary Hill, BSN, CWOCN, WOCC(C), Vancouver Coastal Health; John Garrettson, BA, CWCA, strategic commercial technology consultant, Kane Biotech; Dr. Rohan Pointer, MD, MSc, medical director, medical affairs, Kane Biotech; and Dr. Iris Noland, MD, MCISc, Lakeview Family Health Team. "Since its approval by Health Canada, revyve has been evaluated in a case series with encouraging results. It was shown to convert non-healing wounds to healing wounds in real patients with complex chronic lesions," said Dr. Rohan Pointer, medical director, Kane Biotech. The Canadian case study posters featured four unique clinical cases, part of a larger series, observing changes in wound size, pain, exudate and tissue regranulation over time in patients with chronic, difficult-to-treat wounds. These included: Observed reduction in wound size over three weeks and reported quality of life improvement in a pressure wound case; 60-per-cent wound size reduction over two months in a venous leg ulcer; Reported pain elimination and exudate reduction in a painful pressure wound; Observed healing progression in a venous leg ulcer with associated pain improvement over six weeks. Dr. Pointer further commented: "At Kane, we are encouraged by the in vitro and early clinical observations shared at these conferences. These insights point to the potential role of revyve in supporting wound hygiene and care for patients with complex lesions." Health care professionals attending both events engaged directly with Kane representatives, received educational materials and participated in product demonstrations of revyve. "Clinical conferences are an opportunity for Kane to reinforce our innovation in wound care," said Dr. Robert Huizinga, interim chief executive officer. "These presentations are an expansion of our market support plan for revyve and demonstrate both the clinical value and commercial potential of revyve. We look forward to presenting additional data throughout this year and next." About Kane Biotech Inc. Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. We seek Safe Harbor.